Bispecific Antibody

Sikander Ailawadhi, MD, discusses what’s new in the multiple myeloma space.

In this video, Tycel Phillips, MD, discusses treatment options available to patients with DLBCL.

In this video, Stephen M. Ansell, MD, PhD, discusses research on the durability of bispecific antibodies, presented at ASH Annual Meeting and Exposition.

In this video, Brian T. Hill, MD, PhD, discusses important research on bispecific antibodies for the treatment of lymphoma presented at ASH Annual Meeting and Exhibition.

MADRID — Hossein Borghaei, DO, MS, discussed results from the PAPILLON trial, which combined amivantamab and chemotherapy as first-line treatment for EGFR exon 20 insertion-mutated non-small cell lung cancer, in a video interview.

MADRID — MEDI5752, a novel bispecific antibody binding to CTLA-4 and PD-1, showed potential as a first-line treatment in patients with advanced clear cell renal cell carcinoma, according to data presented at ESMO Congress.

Bispecific agents appear promising in broadening the treatment landscape in wet age-related macular degeneration and diabetic macular edema, but much remains to be learned about this emerging class of agents.

More than 90% of patients with relapsed or refractory multiple myeloma who received the two highest doses of REGN5459 responded to treatment with the investigational bispecific antibody, results of a phase 1/phase 2 study showed.